journal
https://read.qxmd.com/read/38708377/in-cardiogenic-shock-age-is-not-just-a-number
#1
JOURNAL ARTICLE
Aniket S Rali, Lena Tran, Malcolm Dix, Rochelle Prokupets, JoAnn Lindenfeld, Siva Taduru
No abstract text is available yet for this article.
2024: Cardiac Failure Review
https://read.qxmd.com/read/38708376/the-therapy-and-management-of-heart-failure-with-preserved-ejection-fraction-new-insights-on-treatment
#2
REVIEW
Giulio Balestrieri, Raul Limonta, Enrico Ponti, Anna Merlo, Edoardo Sciatti, Salvatore D'Isa, Mauro Gori, Gavino Casu, Cristina Giannattasio, Michele Senni, Emilia D'Elia
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterised by the presence of diastolic dysfunction and elevated left ventricular filling pressure, in the setting of a left ventricular ejection fraction of at least 50%. Despite the epidemiological prevalence of HFpEF, a prompt diagnosis is challenging and many uncertainties exist. HFpEF is characterised by different phenotypes driven by various cardiac and non-cardiac comorbidities. This is probably the reason why several HFpEF clinical trials in the past did not reach strong outcomes to recommend a single therapy for this syndrome; however, this paradigm has recently changed, and the unmet clinical need for HFpEF treatment found a proper response as a result of a new class of drug, the sodium-glucose cotransporter 2 inhibitors, which beneficially act through the whole spectrum of left ventricular ejection fraction...
2024: Cardiac Failure Review
https://read.qxmd.com/read/38533397/initiation-and-up-titration-of-guideline-directed-medical-therapy-for-patients-with-heart-failure-better-faster-stronger
#3
REVIEW
Edgar Francisco Carrizales-Sepúlveda, Alejandro Ordaz-Farías, José Arturo Vargas-Mendoza, Raymundo Vera-Pineda, Ramiro Flores-Ramírez
Treatment for heart failure has experienced a major revolution in recent years, and current evidence shows that a combination of four medications (angiotensin receptor-neprilysin inhibitors + β-blockers + mineralocorticoid receptor antagonists + sodium.glucose cotransporter 2 inhibitors) offer the greatest benefit to our patients with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality. Unfortunately, despite their proven benefits, the implementation of these therapies is still low...
2024: Cardiac Failure Review
https://read.qxmd.com/read/38464556/red-flags-in-acute-myocarditis
#4
REVIEW
Shahrukh Hashmani, Yosef Manla, Nadya Al Matrooshi, Feras Bader
Acute myocarditis is an inflammatory disease of the heart that may occur in the setting of infection, immune system activation or exposure to certain drugs. Often, it is caused by viruses, whereby the clinical course is usually benign; however, it may also present with rapidly progressive fulminant myocarditis, which is associated with high morbidity and mortality. This review highlights the critical red flags - from the clinical, biochemical, imaging and histopathological perspectives - that should raise the index of suspicion of acute myocarditis...
2024: Cardiac Failure Review
https://read.qxmd.com/read/38464555/heart-failure-nurses-within-the-primary-care-setting
#5
REVIEW
Loreena Hill, Anne McNulty, James McMahon, Gary Mitchell, Cathy Farrell, Izabella Uchmanowicz, Teresa Castiello
Cardiology services within primary care often focus on disease prevention, early identification of illness and prompt referral for diagnosis and specialist treatment. Due to advances in pharmaceuticals, implantable cardiac devices and surgical interventions, individuals with heart failure are living longer, which can place a significant strain on global healthcare resources. Heart failure nurses in a primary care setting offer a wealth of clinical knowledge and expertise across all phases of the heart failure trajectory and are able to support patients, family members and other community services, including general practitioners...
2024: Cardiac Failure Review
https://read.qxmd.com/read/36891179/pharmacy-challenges-in-cardiac-patient-care-during-the-covid-19-pandemic-lessons-learnt-for-the-future
#6
EDITORIAL
Andrew McRae
No abstract text is available yet for this article.
February 2023: Cardiac Failure Review
https://read.qxmd.com/read/36891178/remote-patient-monitoring-for-patients-with-heart-failure-sex-and-race-based-disparities-and-opportunities
#7
REVIEW
Ioannis Mastoris, Ersilia M DeFilippis, Trejeeve Martyn, Alanna A Morris, Harriette Gc Van Spall, Andrew J Sauer
Remote patient monitoring (RPM), within the larger context of telehealth expansion, has been established as an effective and safe means of care for patients with heart failure (HF) during the recent pandemic. Of the demographic groups, female patients and black patients are underenrolled relative to disease distribution in clinical trials and are under-referred for RPM, including remote haemodynamic monitoring, cardiac implantable electronic devices (CIEDs), wearables and telehealth interventions. The sex- and race-based disparities are multifactorial: stringent clinical trial inclusion criteria, distrust of the medical establishment, poor access to healthcare, socioeconomic inequities, and lack of diversity in clinical trial leadership...
February 2023: Cardiac Failure Review
https://read.qxmd.com/read/36891177/implications-of-extra-cardiac-disease-in-patient-selection-for-heart-transplantation-considerations-in-cardiac-amyloidosis
#8
REVIEW
Lynn Raju Punnoose, Hasan Siddiqi, Julie Rosenthal, Michelle Kittleson, Ronald Witteles, Kevin Alexander
Disease-modifying therapies in both light chain and transthyretin amyloidosis have improved patient functional status and survival. Conceivably, as heart failure may progress despite amyloid therapies, more patients may be considered for heart transplantation. In earlier eras, extra-cardiac amyloid deposits significantly reduced post-heart transplant patient survival and functional status compared to the non-amyloid population. In the modern era, transplant centres have reported improved outcomes in amyloidosis as patient selection has grown more stringent...
February 2023: Cardiac Failure Review
https://read.qxmd.com/read/38020671/epidemiology-clinical-characteristics-and-cause-specific-outcomes-in-heart-failure-with-preserved-ejection-fraction
#9
REVIEW
Chris J Kapelios, Bahira Shahim, Lars H Lund, Gianluigi Savarese
Heart failure (HF) is a global pandemic affecting 64 million people worldwide. HF with preserved ejection fraction (HFpEF) has traditionally received less attention than its main counterpart, HF with reduced ejection fraction (HFrEF). The incidence and prevalence of HFpEF show geographic variation and are increasing over time, soon expected to surpass those of HFrEF. Morbidity and mortality rates of HFpEF are considerable, albeit lower than those of HFrEF. This review focuses on the burden of HFpEF, providing contemporary data on epidemiology, clinical characteristics and comorbidities, cause-specific outcomes, costs and pharmacotherapy...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37942188/biomarkers-to-improve-decision-making-in-acute-heart-failure
#10
REVIEW
Rafael de la Espriella, Gonzalo Núñez-Marín, Pau Codina, Julio Núñez, Antoni Bayés-Genís
Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37602190/cardiovascular-involvement-in-fabry-s-disease-new-advances-in-diagnostic-strategies-outcome-prediction-and-management
#11
REVIEW
Emanuele Monda, Luigi Falco, Giuseppe Palmiero, Marta Rubino, Alessia Perna, Gaetano Diana, Federica Verrillo, Francesca Dongiglio, Annapaola Cirillo, Adelaide Fusco, Martina Caiazza, Giuseppe Limongelli
Cardiovascular involvement is common in Fabry's disease and is the leading cause of morbidity and mortality. The research is focused on identifying diagnostic clues suggestive of cardiovascular involvement in the preclinical stage of the disease through clinical and imaging markers. Different pathophysiologically driven therapies are currently or will soon be available for the treatment of Fabry's disease, with the most significant benefit observed in the early stages of the disease. Thus, early diagnosis and risk stratification for adverse outcomes are crucial to determine when to start an aetiological treatment...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37547123/global-public-health-burden-of-heart-failure-an-updated-review
#12
REVIEW
Bahira Shahim, Chris J Kapelios, Gianluigi Savarese, Lars H Lund
Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64 million people globally. Although the incidence of HF has stabilised worldwide and seems to be declining in developed countries, the prevalence is increasing due to the ageing of the population, improved survival after MI and improved treatment and survival of patients with HF. Yet, HF remains associated with high mortality and morbidity, poor quality of life and functional capacity, and confers a substantial burden to the healthcare system...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37427009/pathophysiological-rationale-and-clinical-evidence-for-neurohormonal-modulation-in-heart-failure-with-preserved-ejection-fraction
#13
REVIEW
Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome resulting from the interaction between cardiac diseases, comorbidities and ageing. HFpEF is characterised by the activation of neurohormonal axes, namely of the renin-angiotensin-aldosterone system and the sympathetic nervous system, although to a lesser extent compared with heart failure with reduced ejection fraction. This provides a rationale for neurohormonal modulation as a therapeutic approach for HFpEF. Nonetheless, randomised clinical trials have failed to demonstrate a prognostic benefit from neurohormonal modulation therapies in HFpEF, with the sole exception of patients with left ventricular ejection fraction in the lower range of normality, for whom the American guidelines suggest that such therapies may be considered...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37427008/effects-of-sacubitril-valsartan-on-exercise-capacity-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-the-role-of-percentage-of-delayed-enhancement-measured-by-cardiac-magnetic-resonance-in-predicting-therapeutic-response-a-multicentre-study
#14
JOURNAL ARTICLE
Cinzia Nugara, Francesco Giallauria, Giuseppe Vitale, Silvia Sarullo, Giovanni Gentile, Francesco Clemenza, Annamaria Lo Voi, Antonino Zarcone, Elio Venturini, Gabriella Iannuzzo, Andrew Js Coats, Filippo M Sarullo
Background : This study aims to evaluate the cardiopulmonary effects of sacubitril/valsartan therapy in patients with heart failure with reduced ejection fraction (HFrEF), investigating a possible correlation with the degree of myocardial fibrosis, as assessed by cardiac magnetic resonance. Methods : A total of 134 outpatients with HFrEF were enrolled. Results : After a mean follow-up of 13.3 ± 6.6 months, an improvement in ejection fraction and a reduction in E/A ratio, inferior vena cava size and N-terminal pro-B-type natriuretic peptide levels were observed...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37427007/defining-heart-failure-based-on-imaging-the-heart-and-beyond
#15
REVIEW
Fraser J Graham, Antonio Iaconelli, Piotr Sonecki, Ross T Campbell, David Hunter, John Gf Cleland, Pierpaolo Pellicori
Water and salt retention, in other words congestion, are fundamental to the pathophysiology of heart failure and are important therapeutic targets. Echocardiography is the key tool with which to assess cardiac structure and function in the initial diagnostic workup of patients with suspected heart failure and is essential for guiding treatment and stratifying risk. Ultrasound can also be used to identify and quantify congestion in the great veins, kidneys and lungs. More advanced imaging methods might further clarify the aetiology of heart failure and its consequences for the heart and periphery, thereby improving the efficiency and quality of care tailored with greater precision to individual patient need...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37427006/role-of-imaging-in-cardiomyopathies
#16
REVIEW
Vincenzo Castiglione, Alberto Aimo, Giancarlo Todiere, Andrea Barison, Iacopo Fabiani, Giorgia Panichella, Dario Genovesi, Lucrezia Bonino, Alberto Clemente, Filippo Cademartiri, Alberto Giannoni, Claudio Passino, Michele Emdin, Giuseppe Vergaro
Imaging has a central role in the diagnosis, classification, and clinical management of cardiomyopathies. While echocardiography is the first-line technique, given its wide availability and safety, advanced imaging, including cardiovascular magnetic resonance (CMR), nuclear medicine and CT, is increasingly needed to refine the diagnosis or guide therapeutic decision-making. In selected cases, such as in transthyretin-related cardiac amyloidosis or in arrhythmogenic cardiomyopathy, the demonstration of histological features of the disease can be avoided when typical findings are observed at bone-tracer scintigraphy or CMR, respectively...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37397241/epicardial-fat-in-heart-failure-with-preserved-ejection-fraction-bad-actor-or-just-lying-around
#17
REVIEW
Mary-Tiffany Oduah, Varun Sundaram, Yogesh Nv Reddy
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised to be strongly associated with obesity and abnormalities in fat distribution. Epicardial fat has been associated with abnormal haemodynamics in HFpEF, with potential for direct mechanical effects on the heart causing constriction-like physiology and local myocardial remodelling effects from secretion of inflammatory and profibrotic mediators. However, patients with epicardial fat generally have more systemic and visceral adipose tissue making determination of causality between epicardial fat and HFpEF complex...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37397240/treatment-of-persistent-left-atrial-appendage-thrombus-in-patients-with-atrial-fibrillation-on-adequate-oral-anticoagulation-pathways-of-care-for-all-comers-and-heart-failure-patients
#18
REVIEW
Josip Katic, Josip Andelo Borovac
In patients with AF, the presence of left atrial/left atrial appendage (LA/LAA) thrombus is related to an increased risk of thromboembolic events. Anticoagulation therapy, either with vitamin K antagonists or novel oral anticoagulants (NOACs) is therefore mandatory in AF with LA/LAA thrombus in order to lower the risk of stroke or other systemic embolic events. Despite the efficacy of these treatments, some patients will have persistent LAA thrombus remaining or may have contraindications to oral anticoagulation...
2023: Cardiac Failure Review
https://read.qxmd.com/read/37387734/imaging-in-heart-failure-with-preserved-ejection-fraction-a-multimodality-imaging-point-of-view
#19
REVIEW
Serkan Ünlü, Özge Özden, Ahmet Çelik
Heart failure with preserved ejection fraction (HFpEF) is an important global health problem. Despite increased prevalence due to improved diagnostic options, limited improvement has been achieved in cardiac outcomes. HFpEF is an extremely complex syndrome and multimodality imaging is important for diagnosis, identifying its different phenotypes and determining prognosis. Evaluation of left ventricular filling pressures using echocardiographic diastolic function parameters is the first step of imaging in clinical practice...
2023: Cardiac Failure Review
https://read.qxmd.com/read/36891063/polypharmacy-in-older-people-with-heart-failure-roles-of-the-geriatrician-and-pharmacist
#20
REVIEW
Maria Stefil, Matthew Dixon, Jameela Bahar, Schabnam Saied, Knievel Mashida, Olivia Heron, Eduard Shantsila, Lauren Walker, Asangaedem Akpan, Gregory Yh Lip, Rajiv Sankaranarayanan
Heart failure (HF) is a common health condition that typically affects older adults. Many people with HF are cared for on an inpatient basis, by noncardiologists, such as acute medical physicians, geriatricians and other physicians. Treatment options for HF are ever increasing, and adherence to guidelines for prognostic therapy contributes to polypharmacy, which is very familiar to clinicians who care for older people. This article explores the recent trials in both HF with reduced ejection fraction and HF with preserved ejection fraction and the limitations of international guidance in their management with respect to older people...
January 2022: Cardiac Failure Review
journal
journal
55933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.